LNCaP prostate cancer cells, in contrast to the PC-3 cells, are androgen-responsive, poorly invasive [23] and do not have specific GRPR binding sites, as assessed by radioligand binding to 125I[Tyr4]-Bombesin [38] and [Ca2+]i mobilization in response to BBS [39]. This evidence concerns the gene BBS2 and prostate carcinoma.